The article addresses the hidden challenges of staffing scalability in Phase III studies, particularly when working with large CROs. It reveals that while these CROs may have vast resources, they often struggle to provide the specialized expertise required for complex trials. The piece emphasizes the need for careful consideration of a CRO’s true capabilities in meeting the specific demands of large-scale studies.
